Group items tagged

Community pharmacists in England have launched a new digital platform called My Local Surgery, enabling patients to access Pharmacy First consultations online. This initiative, a part of the NHS Pharmacy First scheme, facilitates free video consultations for six common conditions, connecting patients with community pharmacists for clinical advice and treatment. The platform, spearheaded by a team of pharmacy, tech, and clinical services experts, including experienced community pharmacists Darren Lingaloo and Gulraj Dhillon, tech specialist Nav Ramiah, and Dr. Adam Kirk, a seasoned NHS and digital healthcare professional, seeks to meet the rising demand for clinical services. Darren Lingaloo, co-founder and chief pharmacist at My Local Surgery, said: "The evolving role of pharmacists is long overdue and has the potential to save millions of GP appointments every year.

The Royal Pharmaceutical Society (RPS) has launched a new revised RPS Professional Standards for Hospital Pharmacy Services at its annual conference held on Friday (11 November). RPS developed the standards through an extensive consultation with the profession, multidisciplinary teams and patients. They are relevant for providers of pharmacy services in acute, mental health, private, community service, prison, hospice and ambulance settings. The revised Standards contain two brand new descriptors - research, audit and quality improvement, and inclusion and wellbeing. Updates have been made to the supporting statements to ensure they reflect current practice and are fit for the future. A new assessment tool has been developed to support organisations either self-assess or peer-assess against the Standards. "For the first time the Standards apply UK wide, having gained support from Pharmacy Forum NI, alongside endorsement from The Association of Pharmacy Technicians UK and other professional groups," RPS said.

The Royal Pharmaceutical Society (RPS) and the charity Marie Curie have developed a consultation on 'professional standards for palliative and end of life care for community pharmacy'. The consultation will be open for four weeks for community pharmacists, organisations with a role in community pharmacy or palliative/end of life care, or patients or carers with first-hand experience of palliative and end of life care to share their views until 1st December 2022. Through this consultation, Society aims to that ensure the standards are clear, relevant, current, and fit for purpose from the perspective of the community pharmacy team, the wider health team and patients/carers. "The final standards will be published in 2023 and will help community pharmacies across the UK to self-assess and continuously improve their palliative, end of life and bereavement care," said RPS.

This Pharmacy First Common Ailments service will help patients seek treatment for seven common conditions directly from a pharmacy without the need for a GP appointment or prescription. Launching on 31 January next year although it is subject to IT being ready, the service will cover ailments including "sinusitis, sore throat, earache, infected insect bites, impetigo, shingles, and uncomplicated urinary tract infections (UTIs)" in women. People with symptoms of the above seven conditions will be supplied with a prescription-only treatment under a Patient Group Direction (PGD). Patients seeking assistance at the pharmacy, whether walk-in or referred by NHS 111, GPs, or other sources, can receive consultations. The new service includes self-referring patients plus referrals, and the Community Pharmacist Consultation Service (CPCS) will also be a part of it.

The NHS plans to train hundreds of pharmacy staff, expanding their ability to provide advanced clinical services and assume wider roles in dispensing medicines. With a targeted launch in September, up to 840 pharmacy technicians can join in the training programme. The online modules will cover consultation skills, therapeutics, clinical decision-making, assessment skills, and service improvement. "Community pharmacies are pivotal in local communities, and this novel training scheme empowers them to extend their service offerings to a wider patient base," said Health Minister Neil O'Brien. "Through our investment in the workforce, we're bolstering the implementation of the Pharmacy First initiative with £645 million, ensuring patients have access to expert assistance for various common ailments, including urinary tract infections and earaches." NHS said the training will offer flexibility to align with the working schedules and prior experience of community pharmacy technicians. It will combine independent online e-course study, educational supervision, and clinical skills training. Facilitated workshops will concentrate on enhancing clinical assessment skills and applying knowledge and skills through case studies, practice activities, and group discussions.

The Department of Health and Social Care (DHSC) has published plans to amend current pharmacy legislation on dispensing errors and clarify how registered pharmacies are governed. The Department's response to a public consultation on rebalancing medicines legislation and pharmacy regulation programme first proposed in summer 2018 was delayed due to Brexit and the Covid-19 pandemic. The programme aims to clarify and strengthen the organisational governance arrangements of registered pharmacies, specifically to define and clarify the core purpose of the Responsible Pharmacist and Superintendent Pharmacist roles. It will also give the General Pharmaceutical Council (GPhC) powers to define in professional standards how those roles are fulfilled.

A recent report by the Company Chemists' Association (CCA) has revealed a significant disparity in patient engagement with the Pharmacy First service across the UK. In response, Santosh Sahu, Founder and CEO at Charac, has emphasised the need for technological reform to address "the interoperability gap between pharmacists and GPs". Sahu identified the lack of GP referrals for Pharmacy First consultations as a key issue, attributing it to inadequate IT infrastructure. He urged the sector to "implement technological reforms to enhance interoperability between pharmacists and GPs, enabling them to share patient records, identify care pathways, and address health needs more effectively".

Community Pharmacy England (CPE) is organising a series of webinars to help pharmacy owners and their teams to prepare for the implementation of new Pharmacy First service, and changes to the Contraception and Hypertension Case-Finding Services. Beginning from 5th December, the webinars would be conducted throughout December and January, with support from NHS England and the Centre for Postgraduate Education (CPPE), the organisation announced on Thursday (30 November). During the online seminars, pharmacy teams will be explained about the individual services announced, and things to consider before they start providing, or expand their offering of, these services. Each webinar will have CPE's Services Team, who would be leading the team, and policy experts from NHS England and CPPE as speakers.

Talk of hub and spoke models has been rumbling on for as long as I can remember. The topic has once again hit the headlines as the government announced a fresh consultation for its proposed changes, calling on all interested parties to submit their views by 8th June. The argument for hub and spoke is to allow independents to have the same level playing field as the larger groups who have been operating this model for some time. The government also sees significant efficiency gains in centralisation, arguing this will free pharmacists time away from dispensing to focus on clinical services. The latest consultation advocates two models being created. In the first model, the dispensed medication is sent back to the spoke. In the second model, the completed medication can be sent out directly to the patient. The latter is a new concept which could open up new opportunities in how services are delivered. Pharmacies could effectively outsource the entire dispensing and delivery to housebound patients and care homes allowing pharmacies to take on new business without having to worry about logistics and geography.

Community pharmacy contractors eligible under the revised Pharmacy Access Scheme (PhAS) will receive their first of the new monthly payments with the January reconciliation payment due on April 1, 2022. Details of the revised version of the PhAS that commenced from January 1, was published in August 2021, with contractors receiving letters from the NHS Business Services Authority (NHSBSA) indicating their eligibility in the Autumn, PSNC said in an update. Payments under the scheme are dependent on registration on NHSBSA's Manage Your Service (MYS) portal to provide the Community Pharmacist Consultation Service(CPCS). Meanwhile, the review application window is now open for contractors, which would enable the NHS England and NHS Improvement (NHSE&I) to correct inaccuracies related to a pharmacy's distance criteria/calculation.

As the general election campaign heats up, major political parties - including Labour, the Conservatives, the Liberal Democrats - have released their manifestos, detailing their plans and visions for the future of community pharmacy. While the Conservative Party promises to expand Pharmacy First initiative, Labour pledges support for small businesses, with plans to overhaul the business rates system. The Liberal Democrats' election manifesto commits to developing a fairer and more sustainable long-term funding model for pharmacies. Announcing their plans recently, Prime Minister Rishi Sunak stated that they are investing in community care services to secure the future of the NHS and make healthcare more accessible. The Conservatives plan to fund these initiatives by cutting NHS managerial positions back to pre-pandemic levels and halving the government's management consultancy expenditure.

The Medicines and Healthcare Products Regulatory Agency (MHRA) is considering the reclassification of Aquiette 2.5mg tablets contains oxybutynin hydrochloride that is used to treat women with milder symptoms of overactive bladder from Prescription-Only-Medicine (POM) to Pharmacy (P) medicine. The agency is encouraging pharmacists, GPs and other health care professionals, the public and women to take part in the reclassification consultation to make a treatment for overactive bladder available for women without the need for a prescription. Public consultation on a set of proposals to make Aquiette 2.5mg Tablets (oxybutynin hydrochloride) available from pharmacies will close on 13 May, 2022. It would be the first time a medicine for the treatment of overactive bladder would be available without prescription, if the reclassification consultation receives positive responses. After the decision is made to reclassify this treatment, pharmacists will have access to training materials and a checklist to enable them to identify women who can be supplied this medicine safely.

Maxwellia has appointed Ian Adamson as strategic advisor to shape the next phase of pharmacy medicine launches - a process which involves identifying and converting suitable prescription only medicines into versions people can choose to buy under the supervision of a pharmacist. Ian brings over 30 years' international consumer health and personal care experience to the Maxwellia team. He is currently an advisor to the board of the UK independent pharmacy chain Day Lewis plc, an advisor to the board of Spanish healthcare company ReVa Europe S.L and board advisor to East Midlands Pharmaceuticals Ltd. Prior to this Ian was Chief Commercial Officer and a main board director at SSL International plc (prior to its sale to Reckitt Benckiser) with responsibility for a $1bn portfolio of brands, which included Durex and Scholl. Ian's appointment follows the landmark reclassification of the progestogen only pill by the MHRA, a change spearheaded by Maxwellia, and the company's subsequent launch of its first product Lovima in July 2021; and the current MHRA public consultation on the reclassification of Maxwellia's new pharmacy brand, Aquiette 2.5mg Tablets (Oxybutynin Hydrochloride) for the treatment of overactive bladder symptoms which are not adequately controlled by bladder training alone.

NHS Greater Glasgow and Clyde has appointed Jennifer Laskey as Scotland's first consultant pharmacist, marking a significant step forward for pharmacy profession in the country. Laskey's new role involves providing support to the West of Scotland Cancer Network, where she will play a pivotal role in enhancing healthcare outcomes. Her appointment underscores the commitment of NHS Greater Glasgow and Clyde to improving patient care and highlights the growing importance of pharmacist-led initiatives in Scotland's healthcare landscape. Laskey, a pharmacist from Scotland, will extend her expertise to bolster the West of Scotland Cancer Network, aiming to enhance outcomes and survival rates across various healthcare settings. As part of recruitment to become a consultant pharmacist, Laskey obtained credentials from the RPS serving in an accredited consultant post ensuring standardisation across the UK for patients and the system.

The Department of Health and Social Care (DHSC) has finally published its response to the 2022 consultation on hub and spoke dispensing. Considering the consultation evidence and further discussions, the government has expressed its intention to progress the proposals for enabling hub and spoke models across different legal entities as soon as possible. This will be achieved by using the enabling powers outlined in Part 2 of the Medicines and Medical Devices Act 2021 (MMDA) to amend the Medicines Act 1968 and the HMRs. Furthermore, the DHSC has decided to proceed with the implementation of the two models of hub and spoke dispensing that it consulted on. The government response to the consultation reads: "Having considered the responses, the government intend to proceed to implement the necessary changes to medicines legislation to remove the current restrictions that prevent the hub and spoke dispensing models from operating across different legal entities found in section 10 of the Medicines Act 1968.

The Department of Health and Social Care (DHSC) today (19 October) issued its official response to an evaluation conducted by an independent expert panel from the Health and Social Care Committee (HSCC) regarding government commitments in the pharmacy sector. The joint agreement between DHSC, NHSE, and CPE (Community Pharmacy England) under a five-year plan commitment to review the funding model, however, the current status is "continue to monitor and discuss progress". The government has claimed that the panel's rating has "not been met" and still "requires improvement". However, the funding "remains subject to affordability and consultation with the sector on the activity that can be delivered within that funding envelope".

The GP Community Pharmacist Consultation Service (GP CPCS) is also delivering 'unexpected' insights to help transform patient care and facilitate integrated working between pharmacists and GPs across Greater Manchester. Since April 2021, almost 14,000 appointments have been referred using the GP CPCS across the Greater Manchester Health and Social Care Partnership - a figure that is growing as its success gathers pace and they continue to support practices to increase referral activity. Joshua Nolan, a pharmacist at Internet Pharmacy in Heywood, one of the first in the area to join the referral service, said: "The number of patients we're seeing from GP CPCS has been building consistently month-on-month. On average we see around 50 patients, but recently we recorded 53 in just one week." The pharmacist, who has been practising for six years and is also an independent prescriber, believes the GP CPCS has helped bring about more awareness to the clinical services community pharmacy can offer.

Britain's health regulator is poised to announce that hormone replacement therapy (HRT) will be made available over the counter for the first time, the Daily Telegraph has revealed. The newspaper first reported on Tuesday (February 1) that watchdogs were set to propose a reclassification of the medication so women are able to access it in a pharmacy without a prescription. Every year, some 1.5 million women experience difficult menopausal symptoms, such as hot flushes, night sweats, sleep disturbance and a variety of emotional problems. But only a tenth of them are prescribed HRT, following a consultation with a GP or specialist. According to the newspaper, the latest proposal aims to improve convenience so that women are able to access HRT more easily, without needing a GP appointment.

The Royal Pharmaceutical Society (RPS) is refreshing its Professional Standards for Homecare Services and will be shared for consultation in August to allow comment and input on the updated content. The final version is expected to be completed in the autumn. The standards were originally published in 2013 and are a framework to support teams providing and commissioning homecare services. Homecare medicines services deliver medication, and any necessary associated care, direct to the patient's home with their consent. The standards help patients experience a consistent quality of homecare services, irrespective of provider, will protect them from avoidable incidents and help them get the best outcomes from their medicines. Jennifer Allen, The Chief Pharmaceutical Officer's Clinical Fellow leading the refresh at RPS said: "It has been 10 years since the first set of Homecare Standards were published, so it is important that they are reviewed and brought up to date to reflect current service design, medicine pathways and delivery models to ensure patients receive safe and effective medication supply and associated care."

HRA Pharma's progestogen-only contraceptive pill, Hana, has won the 'Special Achievement Award' at the Nicolas Hall awards. The awards took place on May 5, 2022 in Athens. HRA's Marketing Director for the UK, Ireland and the Nordics, Kate Evans, was in attendance to represent the Hana team and accept the award. The Hana pill became available in July 2021 for women in the UK to purchase without a prescription following a pharmacy consultation. The launch has made it easier for women to access effective daily contraception. This reclassification made HRA Pharma one of the leaders in this new healthcare category. The switch followed the authorisation of reclassification of desogestrel by UK regulator MHRA. Hana was one of the first products to enter this new market.